Ushering in a New Era in the Treatment of Chronic Kidney Disease and Anemia: Appreciating the Patient Burden, Exploring Pathways and Pathogenesis, Reflecting on the New and Emerging Data

Target Audience
This educational activity has been designed for US-based nephrology healthcare professionals (HCPs), including nephrology physicians, physician assistants (PAs), nurse practitioners (NPs), and residents.

Program Overview
Relatively recent advancements in the understanding of the pathophysiology of CKD-associated anemia has led to the discovery of viable treatment targets, yet nephrologists may lack awareness of these therapeutic developments. Additionally, certain healthcare disparities may limit comprehensive management across the broader population of patients with anemia and CKD, consequently increasing the global burden of this complication. To ensure appropriate care and outcomes for patients, nephrologists require up-to-date education on the pathophysiology of anemia and CKD, burden of disease, current and emerging treatment options, and barriers to care.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Summarize the prevalence and burden associated with anemia in patients with CKD
Describe the rationale of targeting the PHI/HIF for the treatment of anemia in CKD
Cite the efficacy and safety data of novel agents used to manage anemia in CKD
Recognize disparities in the management of anemia in CKD